Gerber Kawasaki Wealth & Investment Management Cellectis S.A. Transaction History

Gerber Kawasaki Wealth & Investment Management

$1.98 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 11, 2022	SELL	$8.01 - $12.84 $40 - $64	-5 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $59 - $80	5 New	5 $0

Others Institutions Holding CLLS

# of Institutions

Shares Held

11.2M

Call Options Held

2.8K

Put Options Held

17.9K

Long Focus Capital Management, LLC San Juan, PR

4.62M
Shares

$8.73 Million
0.35% of portfolio
Capital International Investors Los Angeles, CA

1.85M
Shares

$3.49 Million
0.0% of portfolio
Credit Suisse Ag Zurich, V8

1.44M
Shares

$2.72 Million
0.0% of portfolio
Ubs Asset Management Americas Inc Chicago, IL

1.44M
Shares

$2.72 Million
0.0% of portfolio
Baillie Gifford & CO

708K
Shares

$1.34 Million
0.0% of portfolio

View Full List

About Cellectis S.A.

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $86M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

More about CLLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gerber Kawasaki Wealth & Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Gerber Kawasaki Wealth & Investment Management with notifications on news.

Account